In last trading session, Taysha Gene Therapies Inc (NASDAQ:TSHA) saw 2.51 million shares changing hands with its beta currently measuring 0.24. Company’s recent per share price level of $3.22 trading at $0.08 or 2.55% at ring of the bell on the day assigns it a market valuation of $602.20M. That closing price of TSHA’s stock is at a discount of -20.81% from its 52-week high price of $3.89 and is indicating a premium of 84.47% from its 52-week low price of $0.50. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.34 million shares which gives us an average trading volume of 2.72 million if we extend that period to 3-months.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Upright in the green during last session for gaining 2.55%, in the last five days TSHA remained trading in the green while hitting it’s week-highest on Wednesday, 04/10/24 when the stock touched $3.22 price level, adding 5.29% to its value on the day. Taysha Gene Therapies Inc’s shares saw a change of 81.92% in year-to-date performance and have moved 20.15% in past 5-day. Taysha Gene Therapies Inc (NASDAQ:TSHA) showed a performance of 43.11% in past 30-days. Number of shares sold short was 15.81 million shares which calculate 4.8 days to cover the short interests.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Statistics highlight that Taysha Gene Therapies Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 27.78% of value to its shares in past 6 months, showing an annual growth rate of 59.38% while that of industry is 21.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 60.70% in the current quarter and calculating 71.10% increase in the next quarter. This year revenue growth is estimated to fall -37.50% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.41 million for the same. And 8 analysts are in estimates of company making revenue of $2.42 million in the next quarter that will end on Jun 2024. Company posted $4.71 million and $2.4 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -48.80% while estimating it to be 1.00% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -137.69% during past 5 years.
TSHA Dividends
Taysha Gene Therapies Inc is more likely to be releasing its next quarterly report between May 09 and May 13 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Insiders are in possession of 24.77% of company’s total shares while institution are holding 69.75 percent of that, with stock having share float percentage of 92.71%. Investors also watch the number of corporate investors in a company very closely, which is 69.75% institutions for Taysha Gene Therapies Inc that are currently holding shares of the company. Vanguard Group Inc is the top institutional holder at TSHA for having 1.59 million shares of worth $1.05 million. And as of Jun 29, 2023, it was holding 0.85% of the company’s outstanding shares.
The second largest institutional holder is Tybourne Capital Management (HK) Limited, which was holding about 1.5 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 0.80% of outstanding shares, having a total worth of $0.99 million.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 1.16 million shares of worth $0.77 million or 0.62% of the total outstanding shares. The later fund manager was in possession of 0.81 million shares on Aug 30, 2023, making its stake of worth around $2.6 million in the company or a holder of 0.43% of company’s stock.
